Navigation Links
Silence in Biological Technology

National Ovarian Cancer Coalition and PureOlogy to Host First Annual 'NOCC and PureOlogy's Walk to Break the Silence on Ovarian Cancer'

- CSI: Miami Star and NOCC Spokesperson, Eva La Rue, Lends Her Support as the Celebrity Host to Help Educate Women Nationwide About Ovarian Cancer - LOS ANGELES, Sept. 6 /PRNewswire/ -- Today the National Ovarian Cancer Coalition (NOCC) and PureOlogy, its national haircare and styling partner,...

Organizational Changes at Silence Therapeutics

LONDON, July 17 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN), a leading European RNAi focused biotechnology company, announces that for personal reasons, Jeffery Vick has resigned as Group CEO and left the Company. The Board of Directors has appointed Iain Ross, currently Non-E...

FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry

Quark Pharmaceuticals to develop drug candidate for prevention and treatment of delayed graft function in kidney transplantation LONDON, June 25 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN) today announces that the U.S. Food and Drug Administration (FDA) has approved a Qua...

Stem cells' 'suspended' state preserved by key step, scientists report

...y occurring process in which small RNAs bind to other RNAs to increase or decrease their activity.) In this case, the scientists used the technique to silence Chd1. When they did so, embryonic stem cells could not make the full range of specialized cells. In a laboratory test used to simulate normal cell...

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

...) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from silence Therapeutics and from Alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in...

Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting

...) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from silence Therapeutics and from Alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in...

Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent

...rcial Protection LONDON, July 31 /PRNewswire/ -- silence Therapeutics plc (AIM: SLN), a leading European RN...ith one or more "overhangs" and specifically cover silence Therapeutics' proprietary siRNA molecules, known a...ce in January 2007. Iain Ross, Chairman & CEO of silence Therapeutics, said, "This is a major milestone for...

Silence Therapeutics Patent Update

... LONDON, July 30 /PRNewswire/ -- silence Therapeutics plc (AIM: SLN), a leading European RN...he official information has been reviewed. About silence Therapeutics plc (http://www.silence-therapeutics.com ) silence Therapeutics plc (AIM: SLN) is a leading European ...

Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027

... to Grant Patent LONDON, July 23 /PRNewswire/ -- silence Therapeutics plc (AIM: SLN), a leading European RN... internal product candidate. This patent will give silence broad exclusivity not only for Atu027, but for any...nal and lung cancers. The candidate is designed to silence the function of a novel kinase protein involved in...

Principle of Recursive Genome Function Supersedes Dogmas; By Andras Pellionisz, Online Ahead of Print; (Scientific Visionary Vindicated)

...nned. Thirty major papers shredded long-held views and printed staggering statements such as "the concept of genes is a myth." A deafening silence ensued. Rather than heeding advice of Dr. Collins of "re-thinking long-held beliefs" research went "genome-wide" for more dat...

Silence Therapeutics Announces Successful Opposition of Glover Patent

... LONDON, July 11 /PRNewswire/ -- silence Therapeutics plc (London AIM: SLN), a leading Euro... decision. Jeff Vick, Chief Executive Officer of silence Therapeutics, said, "The Glover patent was arguabl... of RNA interference." Notes to Editors: About silence Therapeutics plc ( http://www.silence-therapeutics...

Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference

...on, Quark believes this was the first siRNA delivered systemically in a human clinical trial. The Company has licenses for AtuRNAi(TM) technology from silence Therapeutics and additional RNAi intellectual property from Alnylam Quark is headquartered in Fremont, California and operates research and developm...

Possible new approach to purifying drinking water

...neering at Dukes Pratt School of Engineering. Our data showed that we could silence the action of a specific gene in a fungus in water, leading us to believe t...essential, yet easy to monitor, gene. They are now testing this approach to silence or block genes essential to the viability of the pathogen. They are also...

Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School

...i NPX delivery technology is its ability to incorporate multiple siRNAs in a single drug product. These multi-targeted therapeutics can simultaneously silence several mRNAs that represent parallel or synergistic elements of the same disease pathway resulting in a more comprehensive and/or novel therapeutic p...

OPKO Health Announces Issuance of U.S. Patent Covering the Use and Administration of Certain Anti-VEGF siRNA's, Including Its Phase III Compound Bevasiranib

...censed to OPKO on a worldwide basis through an agreement with the University of Pennsylvania. Bevasiranib is a first-in-class siRNA drug designed to silence the genes that produce vascular endothelial growth factor, believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first...

Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery

... LONDON, March 13 /PRNewswire-FirstCall/ -- silence Therapeutics plc (AIM: SLN) today announces a coll...he delivery of siRNA molecules. The deal builds on silence Therapeutics' leading expertise in the delivery of...o AstraZeneca. As a result of today's agreement, silence Therapeutics and AstraZeneca will work together to...

EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes

...expression, and DNA methylation and histone deacetylation are two of the more studied epigenetic regulators of gene expression. Epigenetic changes can silence gene expression and, unlike DNA mutations, may be reversed by targeting the mechanisms involved. The silencing of key cell cycle control genes and tum...

Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes

... the more studied epigenetic regulators of gene expression. Epigenetics refers to changes in the regulation of gene expression. Epigenetic changes can silence gene expression and, unlike DNA mutations, may be reversed by targeting the enzymes involved. The silencing of key cell cycle control genes and tumor ...

Technology as the engine of business innovation

... Forget about asking whether technology drives business or business drives technology. Stop worrying about whether or not technology is strategic. silence all the rattling about how superior this technology is to that technology. In technology, as with love, there are certain questions that if you have t...

The black hole of corporate branding

...hould we blame them or the floods of junky ad messages climbing on each other? Customers are now like quiet nocturnal creepers; they go hunting in the silence of the night in the cyber-jungles searching for cheapest deals. They know how to find what they need and know exactly what to get. Should we simply...

Mirus Bio awarded patent on RNA delivery

...is a cellular process in which nucleic acids, which convey genetic information, are delivered in short sequences and used to regulate - to suppress or silence - gene expression and protein production in animals and humans. The company believes the new delivery method, combined with RNA interference, creates ...

RNA Interference and Gene Silencing: History and Overview

...les of dsRNA per cell was sufficient to completely silence the homologous gene's expression. Further... It is therefore possible to use long dsRNAs to silence specific genes in these specific mammalia...tract">Abstract ) Guru T. (2000). A silence that speaks volumes. Nature 404 , 80...

Visualizing siRNA in Mammalian Cells: Fluorescence Analysis of the RNAi Effect

... this does not appear to occur in mammalian cells since siRNA made against one splice form of a particular gene does not silence other splicing variants (Tom Tuschl, personal communication, March 2002). Within the cell, siRNA becomes associated with...

Test More siRNAs for Less

...e chemistry and subsequent purification. siRNAs prepared using the Silencer siRNA Construction Kit were used to silence GFP expression in HeLa cells (Figure 2). Figure 1. The Silencer siRNA Construction Kit Procedure ....

Superior Gene Silencing Using Adenoviral Vectors

...performed with antibodies to Ataxin-3 and GAPDH (as a control), and the siRNAs produced by the viruses were able to specifically silence the allele to which they were designed. The Complete Adenoviral Production System ...

Optimize Transfection of siRNAs for RNAi

...in many cell types. Good Transfection is Critical The ability of small interfering RNAs (siRNAs) to silence gene expression is proving to be invaluable for studying gene function in cultured mammalian cells. siRNAs can be transi...

Optimizing siRNA Transfection for RNAi

... Efficient Transfection is Critical The ability of small interfering RNAs (siRNAs) to silence gene expression is proving to be invaluable for studying gene function in cultured mammalian cells. Quite of...

Drive Long-Term Silencing with CMV Vectors

...se II promoter. While it is possible to use such vectors to produce stable cell lines expressing siRNAs that silence their targets, there are, to date, very few published accounts of doing so (Xia 2002). One explanation for t...

Optimizing Chemical Transfection and Electroporation of siRNAs

...s. Good Transfection is Critical The ability of small interfering RNAs (siRNAs) to silence gene expression is proving to be invaluable for studying gene function in cultured mammalian cells. siRNAs o...

IMPROVE SILENCING SUCCESS: siRNAs THAT WORK BETTER!

...ted siRNAs As more is learned about siRNAs, it is becoming increasingly clear that using highly potent siRNAs that efficiently silence their target gene at low siRNA concentrations is advantageous. Transfection of low siRNA concentrations reduces the potential fo...

Delivering siRNA Using Adenoviral Vectors

...CMV System were developed by Beverly Davidson and colleagues at the University of Iowa. This vector has been used by that lab to silence a number of genes in HeLa cells and adult mice (1). Figure 1. Silencing of GAPD...

Detecting miRNA & siRNA

...search. In one, small double-stranded RNAs (dsRNAs) called small interfering RNAs (siRNAs) have been used to silence the expression of specific genes at the post transcriptional level by a pathway known as RNA interference (R...

Inducing RNAi with siRNA Cocktails Generated by RNase III

...er UV light. 1B. RNase III derived siRNA cocktails silence GAPDH, La and c-FOS. GAPDH and La siRNA... dsRNA, which in turn specifically silence target genes. This suggests t...f siRNAs that can effectively silence target genes. The siRNA popul...

Avoid siRNA Design Altogether!

... Silencer siRNA Cocktail Kit (RNase III). The resulting siRNA cocktail, or a chemically synthesized siRNA known to efficiently silence GAPDH, was transfected into HeLa cells. GAPDH protein levels were analyzed by immunofluorescence 48 hrs later. ...

siRNA transfection optimization with the Agilent 2100 bioanalyzer

...r mechanism believed to have antiretroviral effects. dsRNA fragments with homologous sequence to a translated mRNA fragment will effectively silence the expression of the protein by catalyzing the degradation of the complementary mRNA1-4. In RNAi Dicer, an RNase like enzyme, is responsible ...
Other Tags
(Date:10/16/2014)... Washington land managers have a new synthesis of recent ... mixed-conifer (MMC) forests in the two states. , ... Eastern Oregon and Washington: A Synthesis of the Relevant ... general technical report published by the U.S. Forest Service,s ... a request from managers for a synthesis of the ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/15/2014)... 15, 2014 Sandata Technologies, LLC, an ... community-based care, today announced it released a case ... Electronic Visit Verification™ Solution (EVV™)  for Quality Care ... health company founded in 1996 and has five ... The study details the challenges facing ...
Breaking Biology News(10 mins):New report synthesizes best available science on management of moist mixed-conifer forests 2New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Principle ... years, takes pride in manufacturing top-of-the-line absorbent products. ... image of its most popular brand, Tranquility® Premium Protection ... created a new website, gave its packaging a new ... bring the brand message to the public. , The ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
Other Contents